---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000010"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:43:32.228851+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals Receives IND Approval for Phase 2 Study of KIO-101 for Ocular Autoimmune Disease

## Summary
- Kiora received IND approval from FDA for Phase 2 study of KIO-101 for ocular surface disease in autoimmune patients.
- Phase 2 trial will enroll ~120 patients in a multi-center, randomized, double-masked, controlled study assessing safety and efficacy.
- Study expected to begin enrolling patients in Australia in first half of 2023; two concentrations (0.15% and 0.30%) will be tested.
- KIO-101 is a topical DHODH inhibitor; systemic DHODH inhibitors generate ~$2B annually; target market ~3.43M U.S. patients.

## SEC filing metadata
- accession: 0001372514-23-000010
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000010/0001372514-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000010/kprx-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000010
- JSON: https://secwatch.observer/filing/0001372514-23-000010.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.